University of Paris-Est Marne-la-Vallée

LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M 

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Ooredoo, PIA, HPV, B cell, University, Coronaviridae, Biomedical Research, Chlamydia, HIV, Public health, Vaccine Research Center, Government, Vaccine, VRI, Infection, Immune system, UPEC, IQT, Cancer, IMRB, University of Paris-Est Marne-la-Vallée

LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.

Key Points: 
  • LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate.
  • Englehart, Director, IQT International Ltd UK: “We are impressed by LinKinVax’s team and its vision for developing world-class vaccine technology.
  • This new financing, completed in December 2022, includes a seed funding from private shareholders, beginning of 2022.

LINKINVAX Raises €4.350 Million in Funding

Retrieved on: 
Thursday, February 10, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, VRI, Industry, B cell, Medicine, IMRB, Doctor of Philosophy, Coronaviridae, Research, Immune system, Biomedical Research, Cancer, HIV, CD40, PIA, Infection, Technology, Vaccine Research Center, University, Antigen, HPV, CEO, University of Paris-Est Marne-la-Vallée, Vaccine, SOITEC, UPEC, Public health, MD, LinKinVax technology, LinKinVax, LINKINVAX TECHNOLOGY, LINKINVAX

LinKinVax, a clinical-stage biotechnology company is announcing completion of a 4.350 million seed capital funding round.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company is announcing completion of a 4.350 million seed capital funding round.
  • LinKinVax has already risen to prominence in the French sector, with Bpifrance granting it 31 million under a Covid-related PIA PSCP program and Government Plan Relance , in May 2021.
  • LinKinVaxs innovative technology directly targets dendritic cells (DC), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).

LinKinVax and Inserm Transfert Enter Into an Exclusive Worldwide Licensing Agreement Covering Use of an Innovative Vaccine Platform

Retrieved on: 
Thursday, February 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, CEO, UPEC, Entrepreneurship, Immune system, Cell, IMRB, University, MD, VRI, University of Paris-Est Marne-la-Vallée, SOITEC, Technology, Research, Vaccine Research Center, Biomedical Research, HIV, Medicine, Public service, Antigen, Public health, Health, Medical research, Vaccine, Knowledge, Doctor of Philosophy, Severe acute respiratory syndrome coronavirus 2, Industry, CD40, Technology transfer, B cell, National Institute, Chlamydia, Pharmaceutical industry, Inserm, LinKinVax technology, LinKinVax, Inserm Transfert, LINKINVAX TECHNOLOGY, LINKINVAX, INSERM TRANSFERT

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.

Key Points: 
  • LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.
  • LinKinVax is developing a vaccine platform that directly targets dendritic cells.
  • This research has accelerated adaptation of this vaccine platform to several infectious agents, including SARS-CoV-2 with a universal approach to cover multiple variants.
  • LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).

PathogenDx Announces the CE Marking of Its Next-Generation COVID-19 Testing Technology for the Simultaneous Detection of SARS-CoV-2 (COVID-19) and Its Variants

Retrieved on: 
Wednesday, February 2, 2022
Fluorescence, Infection, CEO, Food, DNA, Union, Real-time, University, Sensor, Molecular biology, Ecosystem, Omicron, Biotechnology, Technology, Environment, Adoption, NGS, COVID-19, Laboratory, Medicine, European Parliament, CE, Agriculture, Public health, Health, National Institute, Vaccine, University of Paris-Est Marne-la-Vallée, Severe acute respiratory syndrome coronavirus 2, Food industry, Prefix sum, Mutation, Medical device, Animal

The Technology Provides Medical Laboratories with a Rapid (6 hours), Affordable and Accurate Test for the Detection of SARS-CoV-2 ("COVID-19") and its Variants ("VOC") and ("VOI") without Sequencing

Key Points: 
  • "By 2021, the SARS-CoV-2 virus had mutated more than 30 times - with Omicron jumping the mutation count to an unprecedented level.
  • By the time the sequencing results were available, the data was already weeks old and had lost much of its public health value.
  • With the number of variants appearing as we have seen, receiving results two to three weeks later does not help.
  • This technology will help growing companies deliver safer products and healthier lives, while avoiding billions of dollars in losses due to infection and contamination.